Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PRTA with free AI briefings, catalyst countdowns, and dilution alerts.

PRTA · Prothena Corporation plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$271.4M Cash on Hand
44mo Cash Runway
Follow PRTA by email Get an email when PRTA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PRTA, unsubscribe in one click. Privacy

📣 What PRTA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Birtamimab (NEOD001) Light Chain (AL) Amyloidosis Phase 3 · NCT04973137 Terminated
Prasinezumab Parkinson's Disease Phase 3 · NCT07174310 Recruiting
RO7046015 Parkinson's Disease Phase 2 · NCT03100149 Active not recruiting
PRX002 Parkinson's Disease Phase 1 · NCT02157714 Completed
PRX003 Psoriasis Phase 1 · NCT02630901 Completed
PRX004 Amyloidogenic Transthyretin (ATTR) Amyloidosis Phase 1 · NCT03336580 Terminated
PRX019 Healthy Participants Study Phase 1 · NCT06699680 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PRTA holds $271.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.5M/quarter from operations, an estimated runway of 44 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRTA files for a raise →

👥 Who Owns PRTA

Insiders 4% Other 5%+ holders 10.2% Institutions (260 holders) 85.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 7,199,218 14.02% 2026-06-30
Fennell Todd W. 5%+ holder (13G) 5,248,846 10.22% 2026-08-18
Rubric Capital Management LP Institution (13G, 5%+) 5,000,000 9.74% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 3,587,480 6.99% 2026-06-30
William P Scully
10% owner
Insider 1,693,000 3.30% 2026-11-06
Gene G. Kinney
President and CEO, Director
Insider 68,793 0.13% 2026-07-28
Anne Evans Kingston
Chief Strategy Officer · +100,000 options
Insider 55,782 0.11% 2026-07-28
Brandon S. Smith
Chief Operating Officer
Insider 52,000 0.10% 2026-07-28
Chad J. Swanson
Chief Development Officer · +190,000 options
Insider 40,733 0.08% 2026-07-28
Tran Nguyen
Chief Strategy Officer and CFO
Insider 40,205 0.08% 2026-07-28
Michael John Isaacs
General Counsel & Company Sec.
Insider 35,745 0.07% 2026-07-28
Wagner M. Zago
Chief Scientific Officer · +190,000 options
Insider 34,000 0.07% 2026-07-28

Share count 51,349,796 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PRTA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRTA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.